Suppr超能文献

人内向整流钾离子通道(HERG)小分子激活剂的发现。

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.

作者信息

Kang Jiesheng, Chen Xiao-Liang, Wang Hongge, Ji Junzhi, Cheng Hsien, Incardona Josephine, Reynolds William, Viviani Fabrice, Tabart Michel, Rampe David

机构信息

Department of Medicinal Chemistry, Aventis Pharmaceuticals, Vitry-Sur-Seine, France.

出版信息

Mol Pharmacol. 2005 Mar;67(3):827-36. doi: 10.1124/mol.104.006577. Epub 2004 Nov 17.

Abstract

Many drugs inhibit the human ether-a-go-go-related gene (HERG) cardiac K+ channel. This leads to action potential prolongation on the cellular level, a prolongation of the QT interval on the electrocardiogram, and sometimes cardiac arrhythmia. To date, no activators of this channel have been reported. Here, we describe the in vitro electrophysiological effects of (3R,4R)-4-[3-(6-methoxyquinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid (RPR260243), a novel activator of HERG. Using patch-clamp electrophysiology, we found that RPR260243 dramatically slowed current deactivation when applied to cells stably expressing HERG. The effects of RPR260243 on HERG channel deactivation were temperature- and voltage-dependent and occurred over the concentration range of 1 to 30 microM. RPR260243-modified HERG currents were inhibited by dofetilide (IC50 = 58 nM). RPR260243 had little effect on HERG current amplitude and no significant effects on steady-state activation parameters or on channel inactivation processes. RPR260243 displayed no activator-like effects on other voltage-dependent ion channels, including the closely related erg3 K+ channel. RPR260243 enhanced the delayed rectifier current in guinea pig myocytes but, when administered alone, had little effect on action potential parameters in these cells. However, RPR260243 completely reversed the action potential-prolonging effects of dofetilide in this preparation. Using the Langendorff heart method, we found that 5 microM RPR260243 increased T-wave amplitude, prolonged the PR interval, and shortened the QT interval. We believe RPR260243 represents the first known HERG channel activator and that the drug works primarily by inhibiting channel closure, leading to a persistent HERG channel current upon repolarization. Compounds like RPR260243 will be useful for studying the physiological role of HERG and may one day find use in treating cardiac disease.

摘要

许多药物会抑制人类醚 - 去极化相关基因(HERG)心脏钾通道。这会导致细胞水平上动作电位延长,心电图上QT间期延长,有时还会引发心律失常。迄今为止,尚未有该通道激活剂的报道。在此,我们描述了新型HERG激活剂(3R,4R)-4-[3-(6-甲氧基喹啉-4-基)-3-氧代丙基]-1-[3-(2,3,5-三氟苯基)-丙-2-炔基]-哌啶-3-羧酸(RPR260243)的体外电生理效应。运用膜片钳电生理学方法,我们发现将RPR260243应用于稳定表达HERG的细胞时,会显著减缓电流失活。RPR260243对HERG通道失活的影响具有温度和电压依赖性,且在1至30微摩尔的浓度范围内出现。RPR260243修饰的HERG电流受到多非利特抑制(IC50 = 58纳摩尔)。RPR260243对HERG电流幅度影响甚微,对稳态激活参数或通道失活过程无显著影响。RPR260243对其他电压依赖性离子通道,包括密切相关的erg3钾通道,未表现出激活剂样效应。RPR260243增强了豚鼠心肌细胞中的延迟整流电流,但单独给药时,对这些细胞的动作电位参数影响不大。然而,RPR260243完全逆转了多非利特在此制剂中延长动作电位的效应。使用Langendorff心脏法,我们发现5微摩尔的RPR260243增加了T波幅度,延长了PR间期,并缩短了QT间期。我们认为RPR260243是首个已知的HERG通道激活剂,该药物主要通过抑制通道关闭起作用,导致复极化时HERG通道电流持续存在。像RPR260243这样的化合物将有助于研究HERG的生理作用,也许有朝一日可用于治疗心脏病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验